CMMB
Price
$3.04
Change
-$0.04 (-1.29%)
Updated
Sep 8, 04:57 PM (EDT)
Capitalization
16.04M
60 days until earnings call
FATE
Price
$0.97
Change
-$0.04 (-3.96%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
116.48M
52 days until earnings call
Interact to see
Advertisement

CMMB vs FATE

Header iconCMMB vs FATE Comparison
Open Charts CMMB vs FATEBanner chart's image
Chemomab Therapeutics
Price$3.04
Change-$0.04 (-1.29%)
Volume$200
Capitalization16.04M
Fate Therapeutics
Price$0.97
Change-$0.04 (-3.96%)
Volume$4.64K
Capitalization116.48M
CMMB vs FATE Comparison Chart in %
Loading...
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMMB vs. FATE commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMMB is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (CMMB: $3.09 vs. FATE: $1.01)
Brand notoriety: CMMB and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMMB: 162% vs. FATE: 115%
Market capitalization -- CMMB: $16.04M vs. FATE: $116.48M
CMMB [@Biotechnology] is valued at $16.04M. FATE’s [@Biotechnology] market capitalization is $116.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMMB’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CMMB’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CMMB and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMMB’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CMMB’s TA Score: 4 bullish, 2 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CMMB is a better buy in the short-term than FATE.

Price Growth

CMMB (@Biotechnology) experienced а -1.59% price change this week, while FATE (@Biotechnology) price change was -2.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.13%. For the same industry, the average monthly price growth was +10.99%, and the average quarterly price growth was +33.00%.

Reported Earning Dates

CMMB is expected to report earnings on Nov 07, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($116M) has a higher market cap than CMMB($16M). FATE YTD gains are higher at: -38.788 vs. CMMB (-57.320). CMMB has less debt than FATE: CMMB (292K) vs FATE (81.3M).
CMMBFATECMMB / FATE
Capitalization16M116M14%
EBITDAN/A-161.6M-
Gain YTD-57.320-38.788148%
P/E RatioN/AN/A-
RevenueN/A8.47M-
Total CashN/A223M-
Total Debt292K81.3M0%
FUNDAMENTALS RATINGS
CMMB vs FATE: Fundamental Ratings
CMMB
FATE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9487
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as CMMB (21). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CMMB (100). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as CMMB (99). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's Price Growth Rating (87) in the Biotechnology industry is in the same range as CMMB (94). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CMMB (100). This means that FATE’s stock grew similarly to CMMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMMBFATE
RSI
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
N/A
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 13 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 5 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BINP0.03N/A
+11.94%
Bionoid Pharma Inc.
NGXXF15.980.69
+4.49%
NGEx Minerals Ltd.
CSPCY5.710.07
+1.24%
CSPC Pharmaceuticals Group Ltd.
NVYTF0.50N/A
N/A
Novacyt Clamart
ANTVF5.10N/A
N/A
Antares Vision SRL SPA

CMMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with OVID. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then OVID could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMMB
1D Price
Change %
CMMB100%
+1.31%
OVID - CMMB
33%
Loosely correlated
-4.65%
ORKA - CMMB
31%
Poorly correlated
+9.22%
HURA - CMMB
31%
Poorly correlated
+0.79%
OCGN - CMMB
28%
Poorly correlated
N/A
FATE - CMMB
28%
Poorly correlated
+3.81%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+3.81%
RXRX - FATE
53%
Loosely correlated
+1.99%
CRBU - FATE
52%
Loosely correlated
+1.08%
MGNX - FATE
52%
Loosely correlated
+3.09%
ALLO - FATE
51%
Loosely correlated
+3.60%
NTLA - FATE
50%
Loosely correlated
+3.79%
More